{
    "nct_id": "NCT03607890",
    "official_title": "Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor",
    "inclusion_criteria": "* Age ≥18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Have metastatic or locally advanced mismatch repair deficient/MSI-H disease.\n* Patients must have received prior PD-1/PD-L1 inhibitor therapy\n* Patients with the presence of at least one measurable lesion.\n* Life expectancy of greater than 3 months.\n* Patients must have adequate organ and marrow function defined by study - specified laboratory tests.\n* Documented left ventricular ejection fraction (LVEF) ≥ 50% - 6 month prior to drug administration.\n* Must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known history or evidence of brain metastases.\n* Require any antineoplastic therapy.\n* History of prior treatment with anti-LAG3.\n* Had chemotherapy, radiation, or steroids within 14 days prior to study treatment.\n* Had any investigational cytotoxic drug within 4 weeks prior to study treatment.\n* Have received any investigational drugs, a live vaccine, any allergen hyposensitization therapy, growth factors or major surgery within 28 days prior to study treatment.\n* Major surgery\n* Hypersensitivity reaction to any monoclonal antibody.\n* Has an active known or suspected autoimmune disease.\n* Has a diagnosis of immunodeficiency.\n* Prior tissue or organ allograft or allogeneic bone marrow transplantation.\n* Requires daily supplemental oxygen\n* History of interstitial lung disease.\n* Significant heart disease\n* History of encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent.\n* Infection with HIV or hepatitis B or C at screening.\n* Has an active infection.\n* Unable to have blood drawn.\n* Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Prior life-threatening toxicity to anti-PD-1, anti-PD-L1, anti-PD-L2,or anti-CTLA4\n* Woman who are pregnant or breastfeeding.",
    "miscellaneous_criteria": ""
}